Let me start this by stating that I rarely post here and do not post at all on the other site anymore. Too much crap on both sites. I have been buying IPIX/CTIX for 4 years now and have not sold any shares that I have acquired. I originally entered for the Kevetrin potential but have been very happy with the Prurisol and Brilacidin development. I work in oral health and have treated oral mucositis cases over the years but none recently. If the case reaches severe, which they often do, then the patient is in such distress that complying with a study regimen which does not seem to be improving their condition and which involves "swishing" (the exact thing that is extremely painful for them) can be unbelievably difficult and is therefore more likely to be terminated. Obviously this could also apply to any patient in this Brilacidin study who was receiving the medication vs. placebo and not improving but one has to consider that if the medication were working as desired then FEWER WOULD DROP OUT due to the discomfort in the treatment group than in the placebo group. I believe that this is the primary reason for the higher than expected numbers for the placebo group (beyond the fact that the historical range for placebo can fluctuate) which make the response rate for the drug look lower than they could and I believe that those behind the scenes who may now be discussing options/deals/etc. well understand this and will be scrupulously analyzing the data for such possibility. Another thing to consider is that these patients often experience sudden changes in health status even if being helped with an isolated sequela such as OM. Such changes can certainly have an effect on their ability to continue daily activities and these changes would almost certainly be more impactful if the OM were worsening and causing general systemic issues. I believe that Drano has it right in post 39995.
As to formulation for Brilacidin delivery that has been discussed, in oral health often we use a fluconasol vaginal troche (obviously not designed for the oral cavity) for treating oral fungal infections BECAUSE it increases exposure to the oral cavity tissues over that received by liquid fluconasol (swish and swallow). It's not rocket science and could probably be relatively easily accomplished by a partner.
All IPO but I have not sold a single share and expect good things soon.
(10)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Category: StocksTotal Views: 142 By : Lucas YoungUpdated: 07-28-2024
Windtree Therapeutics Updates Istaroxime Clinical Development and Trial Data
Providing a thorough update on the clinical and business development of istaroxime, Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company committed to developing creative therapies for critical diseases, has This first-in-class treatment seeks to raise blood pressure, preserve or increase renal function, and strengthen systolic contraction and diastolic relaxation of the heart. In three Phase 2 trials... Continue Reading
SEC Charges Andrew Left and Citron Capital in $20 Million Fraud Scheme
Andrew Left and his company, Citron Capital LLC, have been charged with a $20 million fraud by the Securities and Exchange Commission (SEC). They are activists short sellers. The SEC complaint claims Left recommended stock positions using his Citron Research website and social media platform. He said these positions complemented Citron Capital's and his own investments. Left's recommendations, according to the SEC,... Continue Reading
BurgerFi International Settles Litigation with Lion Point Capital
The owner of Anthony's Coal Fired Pizza & Wings and BurgerFi brand, BurgerFi International, Inc. (NASDAQ: BFI, BFIIW), revealed a sizable settlement with Lion Point Capital, LP. This agreement settles all outstanding claims brought by Lion Point against BurgerFi since the litigation started.
BurgerFi will pay Lion Point $1,350,000 in installments per terms of the settlement. BurgerFi will also issue Lion Point 300,00... Continue Reading
Upcoming Earnings Reports from Tech Giants
The earnings reports from some of the most well-known tech companies—including Microsoft, Apple, Amazon, and Meta Platforms—are much awaited by investors. These studies are vital since they might either calm the market or cause more volatility. A rally in tech stocks stalled in the second half of July, which caused a notable selloff following Tesla and Alphabet's underperformance. The results this week will be a litmus test for the ma... Continue Reading
Trump Champions U.S. Bitcoin Reserve at Bitcoin Conference
At the Bitcoin Conference in Nashville, former US President Donald Trump declared his endorsement of a strategic national bitcoin reserve. He underlined the need to keep the government's seized bitcoin intact and never sell it. This action seeks to confirm his ranking as the preferred candidate for the crypto community. With his audacious crypto policies, Trump's speech drew in over 3,000 people. The announcement fits the increa... Continue Reading
China's Industrial Profits Accelerate in June
China's industrial gains in June increased more quickly, a reflection of good economic trends despite underlying problems. Official figures revealed a 3.6% year-on-year rise in profits, against a 0.7% increase in May. Strong industry output, according to the National Bureau of Statistics (NBS), helped to explain this increase. Since the second quarter also had a major influence, the easing of factory-gate price declines also reflects. This... Continue Reading
Anticipation Builds for Major Tech Earnings
Earnings reports from big tech companies are much awaited by investors, who might shape the direction of American stock markets. Next week Microsoft, Apple, Amazon, and Meta Platforms have to report their quarterly results. The tech industry has shown notable volatility; recent results from Alphabet and Tesla let down the market. This begs questions regarding whether other tech behemoths can satisfy great expectations. These firms' performance i... Continue Reading
Understanding the Basics of Bonds
Bonds are debt instruments companies use to generate capital. Bonds are bought by investors, so the issuing body lends funds. The issuer promises to pay interest at regular intervals in exchange, then return the principal amount on the maturity date. For bondholders, this procedure produces a consistent income source. Bonds can help to lower general volatility and diversify a portfolio. These are often considered safer investments than stocks. Still, knowledg... Continue Reading
Global Stocks Rebound After Four-Day Decline
Friday's global stocks show a notable comeback, the first increase in four sessions. Following a dramatic selloff, this recovery found equities stable among bettering economic signals. Data showing a small rise in the personal consumption expenditures (PCE) price index were published by the Commerce Department. Last month this index—a Federal Reserve preferred inflation gauge—rose 0.1%. The statistics implied a possible relaxation o... Continue Reading
OpenAI Unveils SearchGPT: A New Era in Search Technology
Recently OpenAI revealed a prototype of its own search engine, SearchGPT. This instrument seeks to give users quick, accurate responses backed by pertinent, clear sources. Under alpha testing with a small group of users, SearchGPT promises to transform online information search. This tool is meant to be included into the viral chatbot ChatGPT so that a more natural and simple search experience is enabled. Like in a conversation, users w... Continue Reading